Specify a stock or a cryptocurrency in the search bar to get a summary
Lipum AB
LIPUMLipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden. Address: TvistevAegen 48C, Umeå, Sweden, 907 36
Analytics
WallStreet Target Price
162.2 SEKP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures LIPUM
Dividend Analytics LIPUM
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History LIPUM
Stock Valuation LIPUM
Financials LIPUM
Results | 2019 | Dynamics |